Welcome to our dedicated page for Owens & Minor news (Ticker: OMI), a resource for investors and traders seeking the latest updates and insights on Owens & Minor stock.
Owens & Minor, Inc. (NYSE: OMI) generates a steady flow of corporate, financial, and strategic news as it transitions into Accendra Health, Inc. and refocuses on home-based care. Company press releases and SEC filings describe a multi-step transformation that includes the sale of its Products & Healthcare Services (P&HS) segment, a shift toward a pure play home-based care platform centered on the Patient Direct business, and a corporate name and ticker change to Accendra Health, Inc. and ACH on the New York Stock Exchange.
News related to OMI has recently covered transaction announcements, such as the definitive agreement and subsequent completion of the sale of the P&HS segment to an affiliate of Platinum Equity, along with details of the retained equity stake and associated tax attributes. Earnings releases provide quarterly and year-to-date financial results for continuing operations, which primarily represent the Patient Direct segment and certain functional operations, and discuss management’s views on the company’s financial outlook and strategic priorities.
Investors and observers will also find corporate governance and leadership updates in the news flow, including executive appointments, role changes, and amendments to executive compensation and retirement plans that are connected to the company’s evolving structure. Additional items include announcements of participation in investor conferences, where management presents the company’s strategy and financial profile, and commercial agreements such as the national preferred DME network arrangement involving Apria and Byram with Optum Health.
This news page for OMI serves as a historical archive of Owens & Minor’s communications as it moves toward operating as Accendra Health, Inc. under the ACH ticker. Readers can use it to trace the company’s shift from a combination of hospital-focused distribution and home-based care toward a focused Patient Direct platform, as well as to follow key regulatory filings, transaction milestones, and strategic announcements.
Owens & Minor (NYSE: OMI) completed the sale of its Products & Healthcare Services segment and the Owens & Minor brand to Platinum Equity on December 31, 2025.
The transaction delivered $375 million in cash (subject to customary adjustments), a 5% retained equity stake and preserved tax attributes in excess of $150 million. The publicly traded parent company is being renamed Accendra Health and will operate as a pure-play nationwide home-based care platform focused on the Apria and Byram brands.
Summary not available.
Owens & Minor (NYSE: OMI) announced management will participate in two investor conferences on December 2, 2025. Executives will present at the Citi 2025 Global Healthcare Conference in Miami and host one-on-one meetings at the Bank of America Leveraged Finance Conference in Boca Raton.
At Citi, Ed Pesicka (CEO) and Will Parrish (VP Strategy, Corp Dev & Investor Relations) will take part in a fireside chat at 2:30 P.M. ET and host investor meetings; a live webcast requires registration at least 10 minutes before the event and a replay will be posted on the company’s Investor Relations site. At Bank of America, Jon Leon (CFO) and Alex Miller (VP Tax & Treasury) will hold one-on-one meetings.
Summary not available.
Owens & Minor (NYSE: OMI) will release third-quarter 2025 financial results on Thursday, October 30, 2025, after the New York Stock Exchange closes. The company will host a conference call for investors and analysts the same day at 5:00 p.m. EDT.
Dial-in numbers: toll-free 1-888-300-2035 and toll 1-646-517-7437 with conference ID 1058917. A simultaneous live webcast and a replay will be available on Owens & Minor's Investor Relations events page at investors.owens-minor.com/events-and-presentations/. Owens & Minor is a Fortune 500 healthcare solutions company serving hospital-to-home care with brands Apria, Byram, and HALYARD and about 20,000 teammates worldwide.
Platinum Equity announced a definitive agreement to acquire the Products & Healthcare Services (P&HS) segment from Owens & Minor (NYSE: OMI) on Oct. 7, 2025. Owens & Minor will retain a 5% equity stake in the standalone P&HS business. Headquartered in Richmond, VA, P&HS is a national distributor serving acute care hospitals and health systems. The transaction is expected to close near the end of 2025, subject to regulatory review and customary closing conditions. Platinum Equity reports approximately $50 billion AUM and a ~60-company operating portfolio, positioning it to pursue a carve-out and operational transformation of P&HS.
Owens & Minor (NYSE: OMI) entered a definitive agreement to sell its Products & Healthcare Services (P&HS) segment to Platinum Equity for $375 million cash at closing and will retain a 5% equity stake plus a preferred equity return tied to any future divestiture proceeds. The company will keep specified tax attributes exceeding $150 million. The deal preserves customer continuity and positions Owens & Minor as a pure‑play home‑based care platform. The transaction is subject to customary closing conditions, including Hart‑Scott‑Rodino and other regulatory approvals, and is expected to close near year‑end 2025.
Owens & Minor's (NYSE:OMI) subsidiaries Apria Healthcare and Byram Healthcare have secured a significant national provider agreement with Optum Health, effective September 1, 2025. The partnership integrates with Optum Health's network of 136,000 aligned care delivery physicians and 1,900 clinical sites.
As preferred DME network providers, Apria and Byram will offer a comprehensive range of durable medical equipment products for chronic and acute health needs, including diabetes, sleep health, respiratory care, wound care, urology, and ostomy care. The agreement aims to enhance patient care delivery and streamline the management of medical equipment needs for home-based care.
Owens & Minor (NYSE:OMI) reported Q2 2025 financial results, highlighting a significant strategic shift as it classifies its Products & Healthcare Services segment as discontinued operations due to an impending sale. The company's continuing operations, focused on Patient Direct, showed positive performance with revenue increasing to $681.9 million from $660.4 million year-over-year.
Q2 2025 results showed a GAAP loss from continuing operations of $(83.8) million, compared to $(6.7) million in Q2 2024. However, adjusted net income from continuing operations improved to $20.5 million versus $19.3 million year-over-year. Adjusted EBITDA grew to $96.6 million from $91.1 million in the prior year.
The company is transitioning to become a pure-play Patient Direct business, building on eight years of experience in this space, supported by favorable demographic trends and meaningful scale.
[ "Revenue growth to $681.9M in Q2 2025, up from $660.4M in Q2 2024", "Adjusted EBITDA increased to $96.6M from $91.1M year-over-year", "Adjusted net income from continuing operations improved to $20.5M from $19.3M", "Strategic focus on Patient Direct segment with favorable demographic trends" ]Owens & Minor (NYSE: OMI), a Fortune 500 global healthcare solutions company, has scheduled its second quarter 2025 financial results release for Monday, August 11, 2025, before NYSE trading begins. The company will host a conference call at 8:30 a.m. EDT the same day.
Participants can join via toll-free number (1-888-300-2035) or toll number (1-646-517-7437) using conference ID 1058917. A live webcast will be available on the company's Investor Relations page, with a replay accessible after the presentation.
FAQ
What is the current stock price of Owens & Minor (OMI)?
What is the market cap of Owens & Minor (OMI)?
